First-line pertuzumab combination therapy not cost effective for BC

    This is a preview of subscription content, access via your institution.

    Notes

    1. 1.

      human epidermal growth factor receptor-2

    2. 2.

      2020 US dollars

    Reference

    1. Moriwaki K, et al. Economic Evaluation of First-Line Pertuzumab Therapy in Patients with HER2-Positive Metastatic Breast Cancer in Japan. PharmacoEconomics-Open : 23 Jan 2021. Available from: URL: https://doi.org/10.1007/s41669-020-00254-3

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    First-line pertuzumab combination therapy not cost effective for BC. PharmacoEcon Outcomes News 871, 17 (2021). https://doi.org/10.1007/s40274-021-7455-z

    Download citation